Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

PURPOSE: Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists. Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the onc...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Tap, William D., Villalobos, Victor M., Cote, Gregory M., Burris, Howard, Janku, Filip, Mir, Olivier, Beeram, Murali, Wagner, Andrew J., Jiang, Liewen, Wu, Bin, Choe, Sung, Yen, Katharine, Gliser, Camelia, Fan, Bin, Agresta, Sam, Pandya, Shuchi S., Trent, Jonathan C.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2020
נושאים:
ORIGINAL REPORTS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7238491/
https://ncbi.nlm.nih.gov/pubmed/32208957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02492
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים